ARQT241220C17500
- 0.05
- 0.000.00%
Arcutis Biotherapeutics Newsroom
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18
Arcutis Biotherapeutics Price Target Maintained With a $18.00/Share by Needham
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
Arcutis Biotherapeutics: Strong Commercial Execution and Strategic Growth Initiatives Justify Buy Rating
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
Buy Rating Reaffirmed for Arcutis Biotherapeutics Amid Temporary Challenges and Strong Zoryve Sales Forecast
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $19
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals
Arcutis Biotherapeutics Price Target Announced at $15.00/Share by Jefferies
Arcutis Biotherapeutics Analyst Ratings
Jefferies Initiates Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $15
Buy Rating Initiated on Arcutis Biotherapeutics Amidst Zoryve's Market Expansion and Promising Sales Trajectory